Bayesian and frequentist approaches to the cross-over trial

What is it about?

Current approaches to modeling crossover trials in two treatments are critically reviewed from the perspective of the practical requirements of the drug developer. Frequentist and Bayesian alternatives to approaches currently advocated are considered and compared. It is concluded that it is crucial for the applied statistician working in this field to have an appreciation of the practical medical and pharmacological background.

Featured Image

Why is it important?

Grieve presents a Bayesian approach and Senn presents a frequentist one and each comments on the other's approach.